Bristol Myers Posts $13.07B in Third-Quarter Revenue
BMY sits 45% above its 52-week low of $42.52.
Summary
Bristol Myers reported third-quarter revenue of $13.07B, the first hard number from the quarter, alongside EPS of $1.05 and international revenue that rose 3% to $4B. The company raised its 2026 revenue view to $49.75B-$50.25B from a prior view of $49B-$50B, and its 2026 adjusted EPS outlook range is inclusive of a loss of 60c/Shr net impact from acquired IPRD charges and licensing income. It still sees operating expenses in 2026 at about $16.5B and total worldwide Eliquis revenue increasing 20%-25% in 2026 versus the year-ago period. The quarter lands against a busy backdrop: August merger talks with AstraZeneca, a revived $6.7B Celgene lawsuit, and the September Zola-Cel pause. Revenue alone does not resolve any of those overhangs, though the EPS line and the raised guidance now carry more weight.
At the time of this announcement, BMY was trading at $61.55 on NYSE in the Life Sciences sector, with a market capitalization of approximately $123.7B. The 52-week trading range was $42.52 to $68.64. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.